Request for SCCS Scientific Opinion on Citral
The European Commission requested the SCCS to assess whether the derived safe use levels for Citral by the application of the QRA2 based on the induction of skin sensitization is adequate to protect consumers. A period of 9 months was set for issuing the scientific opinion.

CITRAL

Citral is a mixture of neral and geranial (monoterpene aldehydes) and is widely used as a fragrance and flavor ingredient in food, beverages and several cosmetic and household products. According to the European Cosmetics Regulation (No. 1223/2009), Citral is included in the list of substances which cosmetic products must not contain except subject to the restrictions laid down (Annex III, entry 70). The presence of this ingredient must be indicated in the list of ingredients when its concentration exceeds 0.001% in leave-on products and 0.01% in rinse-off formulations.

The European Commission’s Scientific Committee on Consumer Safety (SCCS) has assessed the safety of fragrance allergens in cosmetic products. The SCCS included Citral in the list of 13 allergens which are most frequently reported and well-recognized as consumer allergens.

REQUEST FOR A SCIENTIFIC OPINION ON CITRAL

The International Fragrance Association (IFRA) has developed and implemented a model for dermal sensitization quantitative risk assessment (QRA). This methodology is based on thresholds (no effect or low effect levels) established in healthy human volunteers and/or in animal experiments and a set of safety factors is applied to derive ‘acceptable exposure level’.

In 2012, it was established the International Dialogue for the Evaluation of Allergens (IDEA) with the aim of improving the risk assessment of fragrance allergens. This project reviewed uncertainty factors, introduced dermal aggregate exposure for fragrance ingredients, resulting in the QRA2 methodology. In 2018, the SCCS issued an opinion stating that it was not yet possible to use the QRA2 to establish a concentration at which induction of sensitization of fragrance is unlikely to occur.

IFRA submitted in 2021 a dossier on derived safe use levels for Citral, by applying the refined QRA2 methodology based on the induction of skin sensitization. Following the new data, the Commission requested the SCCS to assess whether the derived safe use levels for Citral by the application of the QRA2 is adequate to protect consumers.

Two questions are asked to the SCCS:

  • In light of the data provided and taking under consideration the derived upper safe levels using QRA2 methodology for the sensitisation endpoint, does the SCCS consider Citral safe when used as a fragrance ingredient in cosmetic products up to the maximum concentrations provided in the dossier submission?
  • Does the SCCS have any further scientific concerns with regard to the use of QRA2 to derive safe upper levels for Citral or for fragrance allergens in general?

The SCCS accepted this mandate by written procedure on 16 Febuary 2022 and a deadline of 9 months was set.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. European Commission. Request for a scientific opinion on Citral (CAS No. 5392-40-5, EC No. 226-394-6) on sensitisation endpoint. 2022.
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on Fragrance allergens in cosmetic products. SCCS/1459/11. 2012.

further
reading

cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »
cosmetic products

European Commission Recommendation on the Definition of Nanomaterial

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. The European Commission has published a new Recommendation to clarify the definition of ‘nanomaterial’. This definition may serve different policy, legislative and research purposes when addressing materials or issues concerning products of nanotechnologies.

Read More »
cosmetic products

Expected Restriction on the Use of Methyl Salicylate

The European Commission has notified the World Trade Organization (WTO) of a draft amendment to the Regulation (EC) No. 1223/2009 on cosmetic products. Annex III to Regulation will be amended, and the use of Methyl Salicylate in cosmetic products will be restricted.

Read More »